pfizer - Search News

Hosted on MSN · 3h

US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections

AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday. AbbVie and co-developer Pfizer's drug, Emblaveo, is approved in combination with an antibiotic medication for patients 18 years and older with such infections.

MarketWatch · 4h

AbbVie Gets FDA Approval of Intravenous Antibiotic Emblaveo

Emblaveo was jointly developed with Pfizer. AbbVie holds U.S. and Canada commercialization rights, with Pfizer responsible for commercialization in all other areas. Last April, the European Commission granted marketing authorization for treatment of adults with complicated intra-abdominal infections,

Seeking Alpha on MSN · 3h

AbbVie gets FDA approval for antibiotic treatment Emblaveo (update)

AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of aztreonam and avibactam,

Don't call it a comeback: Pfizer returns to Super Bowl with ad pledging to 'knock out' cancer

Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

2don MSN

Pfizer's CEO says he's had dinner with Trump's health secretary pick, RFK Jr.

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's ...

3d

Pfizer shows profit growth from cost cuts and steadier COVID sales

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

FierceBiotech1d

Pfizer builds out oncology team with appointment of Novartis vet Jeff Legos

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

BioPharma Dive1d

Pfizer taps a former Novartis exec to lead cancer drug push

The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

3d

Pfizer’s Covid Boost Overshadowed by Kennedy Threat to Vaccines

Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., ...

FierceBiotech3d

Pfizer axes B7-H4 ADC, triggering $1B impairment charge as blockbuster vision evaporates

Pfizer has ended development of a B7-H4-directed antibody-drug conjugate (ADC), triggering a $1 billion impairment charge. | ...

Crain's New York3d

Pfizer gets unexpected boost from Covid vaccine and pill

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

3d

Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down

Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...

3d

PFE Earnings: Pfizer Stock Jumps on Q4 Beats

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company ...

BioPharma Dive4d

Pfizer drug acquired in $11B buyout confirms benefit in colon cancer

The results could sway U.S. regulators to convert Braftovi’s accelerated clearance in colorectal tumors into a full approval ...

2don MSN

The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results